Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has announced that its new drug, Jilixin (avatrombopag), has received marketing approval from the National Medical Products Administration (NMPA) of China. This approval allows the use of Jilixin for adult patients with thrombocytopenia induced by chronic liver diseases and those with chronic primary immune thrombocytopenia $(ITP)$ who have not responded adequately to previous treatments. Jilixin is a new-generation oral thrombopoietin receptor agonist that increases platelet production, offering a more convenient treatment option without the need for frequent injections. The drug's inclusion in the Class B category of the National Medical Insurance Catalogue further broadens its accessibility. This development marks a significant expansion in Hangzhou Jiuyuan's product offerings in the treatment of thrombocytopenia.